V. Guillem-Porta

Palliative sedation and oncological active treatment at the end of life; Is there any difference between the hospital and at home?

A. Gonzalez-Alvarez, C. Herrero-Vicent, S. García-Agudo, 2017 .

Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial

H. Sommer, M. Untch, P. Kellokumpu-Lehtinen, 2006, British Journal of Cancer.

The Economic Burden of Localized Prostate Cancer and Insights Derived from Cost-Effectiveness Studies of the Different Treatments

J. Martin-Moreno, Luis Castelo-Branco, D. Cantarero-Prieto, 2022, Cancers.

Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients.

J. Baselga, K. Krejcy, M. Namer, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic Value of Tumour-Infiltrating Lymphocytes Changes between Pre and Post-Neoadjuvant Treatment and in Residual Disease in Triple Negative Breast Cancer

J. López-Guerrero, J. Gavilá, Á. Guerrero, 2019, Annals of Gynecology and Obstetrics.

Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy

J. Gavilá, Á. Guerrero, A. Calatrava, 2017, Ecancermedicalscience.

A prognostic index for locoregional recurrence after neoadjuvant chemotherapy

A. Guerrero-Zotano, A. Hernández-Blanquisett, J. Gavilá-Gregori, 2016, Ecancermedicalscience.

Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists

A. Carrato, R. López-López, E. Díaz-Rubio, 2014, Clinical and Translational Oncology.